Compare CORT & AG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | AG |
|---|---|---|
| Founded | 1998 | 1979 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.5B |
| IPO Year | 2001 | 2004 |
| Metric | CORT | AG |
|---|---|---|
| Price | $113.79 | $19.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $96.50 | $21.92 |
| AVG Volume (30 Days) | 823.3K | ★ 7.8M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.12% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $26.08 | $24.41 |
| Revenue Next Year | $26.98 | $10.68 |
| P/E Ratio | $1,224.56 | ★ $143.01 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $10.19 |
| 52 Week High | $126.38 | $32.00 |
| Indicator | CORT | AG |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 47.60 |
| Support Level | $108.25 | $18.43 |
| Resistance Level | $124.30 | $20.00 |
| Average True Range (ATR) | 5.29 | 0.81 |
| MACD | -0.76 | -0.26 |
| Stochastic Oscillator | 61.04 | 26.64 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
First Majestic Silver Corp is in the business of production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. The company owns four producing mines in Mexico, consisting of the Santa Elena Silver/Gold Mine, the San Dimas Silver/Gold Mine, the Los Gatos Silver Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA. Additionally, the firm holds interests in the San Martin Silver Mine and the Del Toro Silver Mine, and several exploration-stage projects. The majority of the company's revenues are from the sale of precious metals contained in dore and concentrate form. It generates maximum revenue from the sale of silver, followed by gold, zinc, copper, and other metals.